“After listening to families and many other organizations at the center of this community, including the Children’s Oncology Group and Angels for Change, we embarked on an aggressive development path to bring a new recombinant erwinia asparaginase option to market, one that will be manufactured under the highest quality standards and provide a reliable supply to meet the needs of our patients.”
July 9 Press Release
Breaking News
We are proud and grateful we could help these Warrior families obtain the life-saving drugs they needed to successfully complete their child’s chemotherapy treatment. Yet we have always maintained our goal is that no parent or patient should ever have to hear, and no doctor should ever have to say, “We don’t have the life-saving drug you need.”
Yahia's Story
Press Release: Summit One 2021
No Child Left Behind
Industry Insights
Every day clinicians wonder if they will have the necessary medicines to treat the patients they serve, which include pediatric cancer patients. Far too often, an oncologist has to treat a pediatric cancer patient with a therapy that is not optimal. As a parent, how would you like to hear that your child has cancer, but the best drug to treat your child is not available and that a suboptimal treatment must be administered? —Martin Van Trieste